{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T15:30:07Z","timestamp":1782487807899,"version":"3.54.5"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T00:00:00Z","timestamp":1764201600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study aimed to evaluate the long-term efficacy and safety of the fully human anti-CD20 monoclonal antibody ofatumumab in refractory generalized myasthenia gravis, with focus on its potential to promote recovery of neuromuscular junction transmission function.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Fourteen refractory patients treated at the Eighth Medical Center of the Chinese PLA General Hospital from March 2023 to June 2024 were included. All had relapsed after maintaining Minimal Manifestation Status for over 1\u00a0year and showed inadequate response to immunosuppressants. Ofatumumab 20\u00a0mg was administered at weeks 0, 1, 2, and 4, followed by additional doses every 4\u20136\u00a0months according to symptoms and CD19-positive B-cell reconstitution. Low-frequency 3-Hz repetitive nerve stimulation of the facial, accessory, and axillary nerves was conducted at baseline and month 12. MG-ADL, QMG, MGC scores and B-cell and T-cell levels were monitored.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The compound muscle action potential (CMAP) decrement of the predominantly involved nerve and the mean decrement across the three tested nerves improved at month 12, indicating enhanced neuromuscular junction transmission. MG-ADL, QMG, and MGC scores declined from month 1, with earlier improvement in bulbar, limb, and neck muscle groups. All patients discontinued corticosteroids by month 12 while remaining clinically stable. B cells stayed at low levels, whereas T-cell counts showed no significant change. Treatment was well tolerated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Ofatumumab provides durable clinical benefit and steroid-sparing effects, and its sustained depletion of CD20-positive B cells may facilitate recovery of neuromuscular junction transmission. These findings support its potential application within the field of regenerative pharmacology.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2025.1728721","type":"journal-article","created":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T05:13:06Z","timestamp":1764220386000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Ofatumumab-mediated CD20+ B-cell depletion promotes neuromuscular junction functional recovery and sustains long-term efficacy in refractory generalized myasthenia gravis"],"prefix":"10.3389","volume":"16","author":[{"given":"Zhuangzhuang","family":"Ren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuping","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yudan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengjie","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhua","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1002\/acn3.314","article-title":"Rituximab in refractory myasthenia gravis: a prospective, open-label study with long-term follow-up","volume":"3","author":"Anderson","year":"2016","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"5985","DOI":"10.2147\/DDDT.S315174","article-title":"Profile of ofatumumab in the treatment of multiple sclerosis: design, development and place in therapy","volume":"18","author":"Awada","year":"2024","journal-title":"Drug Des. Devel Ther."},{"key":"B3","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1111\/j.1749-6632.1998.tb11015.x","article-title":"Reliability testing of the quantitative myasthenia gravis score","volume":"841","author":"Barohn","year":"1998","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"B4","doi-asserted-by":"publisher","first-page":"108877","DOI":"10.1016\/j.clim.2021.108877","article-title":"B cell depletion treatment decreases Th17 cells in patients with rheumatoid arthritis","volume":"233","author":"Bounia","year":"2021","journal-title":"Clin. Immunol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1212\/WNL.0b013e3181dc1b1e","article-title":"The MG composite: a valid and reliable outcome measure for myasthenia gravis","volume":"74","author":"Burns","year":"2010","journal-title":"Neurology"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1404191","DOI":"10.3389\/fimmu.2024.1404191","article-title":"Targeting autoimmune mechanisms by precision medicine in myasthenia gravis","volume":"15","author":"Cavalcante","year":"2024","journal-title":"Front. Immunol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1007\/s00415-019-09498-4","article-title":"Role of complement and potential of complement inhibitors in myasthenia gravis and neuromyelitis optica spectrum disorders: a brief review","volume":"268","author":"Chamberlain","year":"2021","journal-title":"J. Neurol."},{"key":"B8","first-page":"1","article-title":"Chinese guidelines for the diagnosis and treatment of myasthenia gravis (2020 edition)","volume":"28","author":"Chang","year":"2021","journal-title":"J. Neuroimmunol. Neurol. China"},{"key":"B9","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1212\/01.wnl.0000313840.27060.bf","article-title":"Invited article: inhibition of B cell functions: implications for neurology","volume":"70","author":"Dalakas","year":"2008","journal-title":"Neurology"},{"key":"B10","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.nmd.2023.02.005","article-title":"Immunological response after SARS-CoV-2 infection and mRNA vaccines in patients with myasthenia gravis treated with rituximab","volume":"33","author":"Damato","year":"2023","journal-title":"Neuromuscul. Disord."},{"key":"B11","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1212\/WNL.0b013e3182407982","article-title":"Long-lasting treatment effect of rituximab in MuSK myasthenia","volume":"78","author":"D\u00edaz-Manera","year":"2012","journal-title":"Neurology"},{"key":"B12","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.3390\/jcm10112235","article-title":"Myasthenia gravis: epidemiology, pathophysiology and clinical manifestations","volume":"10","author":"Dresser","year":"2021","journal-title":"J. Clin. Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1756286418761697","DOI":"10.1177\/1756286418761697","article-title":"B cell-based therapies in CNS autoimmunity: differentiating CD19 and CD20 as therapeutic targets","volume":"11","author":"Forsthuber","year":"2018","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"B14","doi-asserted-by":"publisher","first-page":"578035","DOI":"10.1016\/j.jneuroim.2023.578035","article-title":"The case report of AQP4 and MOG IgG double positive NMOSD treated with subcutaneous ofatumumab","volume":"376","author":"Gou","year":"2023","journal-title":"J. Neuroimmunol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.jneuroim.2019.05.004","article-title":"Effect of low-dose rituximab treatment on T- and B-cell lymphocyte imbalance in refractory myasthenia gravis","volume":"332","author":"Jing","year":"2019","journal-title":"J. Neuroimmunol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.expneurol.2004.06.005","article-title":"Complement regulators in extraocular muscle and experimental autoimmune myasthenia gravis","volume":"189","author":"Kaminski","year":"2004","journal-title":"Exp. Neurol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"22","DOI":"10.4161\/mabs.22771","article-title":"Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties","volume":"5","author":"Klein","year":"2014","journal-title":"MAbs"},{"key":"B18","doi-asserted-by":"publisher","first-page":"20552173231203816","DOI":"10.1177\/20552173231203816","article-title":"Tolerability of subcutaneous ofatumumab with long-term exposure in relapsing multiple sclerosis","volume":"9","author":"Kramer","year":"2023","journal-title":"Multiple Sclerosis J. Exp. Translational Clin."},{"key":"B19","doi-asserted-by":"publisher","first-page":"325","DOI":"10.2147\/ITT.S255722","article-title":"B-Cell targeted treatments for neuromyelitis optica spectrum disorder: a focus on CD19 and CD20","volume":"10","author":"Levy","year":"2021","journal-title":"Immunotargets Ther."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1278250","DOI":"10.3389\/fneur.2023.1278250","article-title":"Therapeutic effect of ofatumumab in patients with myasthenia gravis: immunoregulation of follicular T helper cells and T helper type 17 cells","volume":"14","author":"Li","year":"2023","journal-title":"Front. Neurol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1007\/s10238-025-01603-4","article-title":"Phenotypic and functional dysregulations of CD8 + T cells in myasthenia gravis","volume":"25","author":"Liu","year":"2025","journal-title":"Clin. Exper. Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1370411","DOI":"10.3389\/fphar.2024.1370411","article-title":"Advancements and prospects of novel biologicals for myasthenia gravis: toward personalized treatment based on autoantibody specificities","volume":"15","author":"Ma","year":"2024","journal-title":"Front. Pharmacol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1001\/jamaneurol.2022.2887","article-title":"Efficacy and safety of rituximab for new-onset generalized myasthenia gravis: the RINOMAX randomized clinical trial","volume":"79","author":"Piehl","year":"2022","journal-title":"JAMA Neurol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1053\/j.ajkd.2023.08.010","article-title":"Ofatumumab in rituximab-resistant and rituximab-intolerant patients with primary membranous nephropathy: a case series","volume":"83","author":"Podesta","year":"2024","journal-title":"Am. J. Kidney. Dis."},{"key":"B25","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1001\/jamaneurol.2016.4190","article-title":"Durability of the rituximab response in acetylcholine receptor autoantibody\u2013positive myasthenia gravis","volume":"74","author":"Robeson","year":"2017","journal-title":"JAMA Neurol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"104031","DOI":"10.1016\/j.msard.2022.104031","article-title":"Simulated treatment comparison of efficacy outcomes for ofatumumab in ASCLEPIOS I\/II versus ocrelizumab in OPERA I\/II for the treatment of patients with relapsing multiple sclerosis","volume":"66","author":"Samjoo","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1277596","DOI":"10.3389\/fneur.2023.1277596","article-title":"Role of complement in myasthenia gravis","volume":"14","author":"San","year":"2023","journal-title":"Front. Neurol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","article-title":"International consensus guidance for management of myasthenia gravis: executive summary","volume":"87","author":"Sanders","year":"2016","journal-title":"Neurology"},{"key":"B29","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1111\/cts.12613","article-title":"Evaluation of the ability of immune humanized mice to demonstrate CD20\u2010Specific cytotoxicity induced by ofatumumab","volume":"12","author":"Semple","year":"2019","journal-title":"Clin. Translational Science"},{"key":"B30","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s42466-019-0023-3","article-title":"SOP myasthenic crisis","volume":"1","author":"Stetefeld","year":"2019","journal-title":"Neurological Res. Pract."},{"key":"B31","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1002\/mus.25597","article-title":"Rituximab treatment of myasthenia gravis: a systematic review","volume":"56","author":"Tandan","year":"2017","journal-title":"Muscle. Nerve."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1111\/ene.14675","article-title":"Performance of different criteria for refractory myasthenia gravis","volume":"28","author":"Tran","year":"2021","journal-title":"Eur. J. Neurol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"e200004","DOI":"10.1212\/NXI.0000000000200004","article-title":"Ofatumumab modulates inflammatory T cell responses and migratory potential in patients with multiple sclerosis","volume":"9","author":"von Essen","year":"2022","journal-title":"Neurol. Neuroimmunol. Neuroinflammation"},{"key":"B34","doi-asserted-by":"publisher","first-page":"E45","DOI":"10.1002\/mus.26707","article-title":"Refractory myasthenia gravis successfully treated with ofatumumab","volume":"60","author":"Waters","year":"2019","journal-title":"Nerve"},{"key":"B35","first-page":"2047","article-title":"Relative fatigability of muscles in response to repetitive nerve stimulation in myasthenia gravis","volume":"89","author":"Witoonpanich","year":"2006","journal-title":"J. Med. Assoc. Thail."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1212\/wnl.52.7.1487","article-title":"Myasthenia gravis activities of daily living profile","volume":"52","author":"Wolfe","year":"1999","journal-title":"Neurology"},{"key":"B37","doi-asserted-by":"publisher","first-page":"315","DOI":"10.4103\/1735-5362.343085","article-title":"Comparison of follicular T helper cells, monocytes, and T cells priming between newly diagnosed and rituximab-treated MS patients and healthy controls","volume":"17","author":"Yahyazadeh","year":"2022","journal-title":"Res. Pharm. Sci."},{"key":"B38","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1002\/mus.25973","article-title":"B cells in the pathophysiology of myasthenia gravis","volume":"57","author":"Yi","year":"2018","journal-title":"Nerve"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1183488","DOI":"10.3389\/fimmu.2023.1183488","article-title":"The case report of MOG and NMDAR IgG double positive encephalitis treated with subcutaneous ofatumumab","volume":"14","author":"Zhang","year":"2023","journal-title":"Front. Immunol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1728721\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T05:13:07Z","timestamp":1764220387000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1728721\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,27]]},"references-count":39,"alternative-id":["10.3389\/fphar.2025.1728721"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1728721","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,27]]},"article-number":"1728721"}}